Eli Lilly gets European marketing rights for Olumiant

The European Commission has granted Eli Lilly & Co. marketing rights for Olumiant, a drug used to treat patients suffering with severe rheumatoid arthritis (RA).
“Despite clinical advances in treatment, many people with RA continue to struggle with debilitating effects of this disease, which can lead to long-term joint damage and disability,” J. Anthony Ware, senior vice president of product development at Eli Lilly, said.
This marks the first global approval for Olumiant.
“The European Commission’s approval of [Olumiant] is an exciting milestone for the RA community in the [European Union],” Steven Stein, chief medical officer at Incyte Corp., said. “We’re confident that (Olumiant) will help to meet the needs of health care providers and their patients as they work toward achieving long-term treatment goals.”